On 24 October 2012, members of BIO Deutschland’s Working Group on Health Policy met in Munich to discuss the topics that it will address in the future.
BIO Deutschland’s diagnostics experts met in Berlin on 8 October 2012 to discuss and evaluate the European Commission’s new proposal for a regulation on in vitro diagnostic medical devices.
In its response to a consultation paper on “state subsidies to promote access to venture capital for small and medium-sized companies (SMEs)”, which it submitted on 5 October 2012, BIO Deutschland called on the EU to improve the current conditions for financing innovations.
BIO Deutschland Issues a Statement on the EU Commission’s Consultation on Plans for a Public-private Partnership in the Life Sciences
On 4 October 2012, BIO Deutschland responded to the EU Commission’s consultation on plans for a public-private partnership (PPP) in life sciences research and innovation under the new EU research framework programme Horizon 2020. In its statement, the association called for the interests and needs of innovative small and medium-sized enterprises (SMEs) in the life sciences to be taken into account to a greater extent than has been the case so far.
On 2 October 2012, BIO Deutschland responded to the European Commission’s Consultation on the Entrepreneurship 2020 Action Plan. In its statement, the association welcomed the fact the European Commission is working on this action plan, which aims to promote the foundation of new companies in Europe.
BIO Deutschland recently welcomed its 300th member, in.vent Diagnostica GmbH, at its ninth general assembly. The association thus reinforced its position as the national and international lobby group for the biotechnology industry. Thirty-four new members joined BIO Deutschland in the last 12 months.